-
Ruxolitinib phosphate: JAK/STAT Research Workflows
2026-08-14
Ruxolitinib phosphate (INCB018424) enables controlled JAK1/JAK2 inhibition across cytokine, autoimmune, hematologic, and solid-tumor models. This workflow-centered guide connects pathway pharmacology with apoptosis, pyroptosis, and mitochondrial-dynamics assays while emphasizing practical controls and troubleshooting.
-
Psora 4 for Reproducible Kv1.3 Assays
2026-08-14
This scenario-based guide explains how Psora 4, SKU B7659, can support mechanistic T-cell proliferation, cytotoxicity, and Ca2+ signaling studies. It covers selectivity, KCNE4-dependent pharmacology, formulation, data interpretation, and practical product-selection criteria.
-
MLKL–Lysosome Signaling in Necroptosis
2026-08-13
The reference study identifies MLKL polymerization-induced lysosomal membrane permeabilization as a critical execution step in necroptosis. By combining live-cell imaging with cathepsin B perturbation, the authors show that lysosomal rupture and cytosolic cathepsin B release occur before plasma membrane failure and promote cell death.
-
TMAO Activates PERK in a Zebrafish NAFLD Model
2026-08-13
The reference study shows that dietary trimethylamine N-oxide (TMAO) can directly produce steatosis, inflammation, liver injury, and fibrosis in zebrafish, extending associations between circulating TMAO and non-alcoholic fatty liver disease. Evidence from zebrafish, HepG2 cells, and hepatic stellate cells identifies PERK signaling as a mechanistically relevant component of TMAO-associated liver pathology, while also defining important limits for translation.
-
MK-0812 and the Gut–Liver Inflammation Axis
2026-08-12
MK-0812 is a selective CCR2 antagonist for resolving how monocyte trafficking contributes to gut–liver inflammation. This article connects functional CCR2 blockade with the compartment-specific mechanisms identified in intestinal TM6SF2 research and offers an assay-focused framework for interpretation.
-
Bazedoxifene: SERM Mechanism and Research Evidence
2026-08-12
Bazedoxifene is a third-generation selective estrogen receptor modulator with tissue-selective activity relevant to postmenopausal osteoporosis and estrogen receptor signaling research. Evidence also supports antimalarial repurposing research through inhibition of Plasmodium growth and hemozoin formation, but this application remains preclinical.
-
Tofacitinib: A Causal Assay Framework for JAK Biology
2026-08-11
Tofacitinib and CP-690550 offer a powerful way to dissect cytokine signaling, lymphocyte behavior, and macrophage state transitions. This article develops a causal assay framework that separates proximal JAK/STAT effects from downstream immunometabolic readouts in rheumatoid arthritis research.
-
Early Life Adversity, Oxytocin, and Innate Defense
2026-08-11
This 2026 Communications Biology study identifies a circuit-level mechanism by which early life adversity impairs looming-evoked innate defensive behavior in mice. Its experiments link social deprivation to reduced oxytocin receptor expression in the superior colliculus, implicate hypothalamic oxytocin projections, and show that intranasal oxytocin can partially ameliorate the behavioral deficit.
-
Pregnenolone Carbonitrile: Designing Better PXR Assays
2026-08-10
Pregnenolone Carbonitrile is a powerful rodent PXR agonist for connecting CYP3A induction, xenobiotic metabolism, and antifibrotic biology. This guide focuses on assay design, orthogonal validation, tissue-specific interpretation, and the emerging hypothalamic–kidney findings that broaden PCN research beyond the liver.
-
Intestinal TM6SF2, MASH, and the Gut–Liver Axis
2026-08-09
A 2025 Nature Metabolism study shows that intestinal epithelial TM6SF2 protects against MASH by preserving barrier function and constraining microbiota- and lipid-mediated signaling to the liver. Genetic deletion, fecal transplantation, cohousing, transcriptomics, and pharmacological intervention together identify LPA movement from the gut as a mechanistic link between intestinal lipid handling and hepatic inflammation.
-
Calpeptin and EV Release in Triple-Negative Breast Cancer
2026-08-08
The reference study systematically tested pharmacological strategies for suppressing extracellular vesicle release from triple-negative breast cancer cells and examined whether residual vesicles retained functional effects. Its central contribution is the combination of quantitative vesicle profiling with recipient-cell migration assays, showing that broad suppression of vesicle output may be necessary to substantially limit the transfer of aggressive traits.
-
Octenidine dihydrochloride: Lab Workflows
2026-08-07
Build reproducible antimicrobial assays around Octenidine dihydrochloride, from solvent selection and serial dilution to membrane-disruption and biofilm readouts. Use the compound as a defined benchmark while translating recent gemini-QAC findings into smarter comparative screens for potency, selectivity, and formulation.
-
Hexetidine (NSC-17764): Applied Workflows for Antimicrobial
2026-08-07
Hexetidine (NSC-17764) stands out for its proven efficacy against oral pathogens and biofilm-forming fungi, with robust, reproducible results in both planktonic and biofilm inhibition assays. This article delivers actionable protocol guidance, troubleshooting insights, and workflow enhancements for researchers seeking high-confidence, strain-specific antimicrobial data.
-
KIR2.1 Inhibition Reduces PASMC Proliferation via TGF-β/Smad
2026-08-06
This study demonstrates that KIR2.1 enhances proliferation and migration of pulmonary artery smooth muscle cells (PASMCs) by activating the TGF-β1/Smad2/3 pathway, implicating its role in pulmonary vascular remodeling. By employing both a KIR2.1 blocker and the ALK5 inhibitor SB 431542, the authors reveal mechanistic insights relevant for pulmonary hypertension research and highlight potential therapeutic strategies targeting this axis.
-
Arachidonic Acid Supplementation Accelerates Humoral Immunit
2026-08-06
The referenced study demonstrates that dietary arachidonic acid (ARA) supplementation can significantly enhance and accelerate the production of neutralizing antibodies following rabies vaccination in mice and humans. These findings reveal new mechanistic insight into how polyunsaturated fatty acids, such as ARA, can modulate B cell activation and suggest dietary strategies for improving vaccine efficacy.